Allergan, Inc. v. Alcon Laboratories, Inc.
- Case Date: 7/19/2002
- Project Name: Health Care Project
On December 1, 2003, the U.S. Supreme Court declined to review an appeals court decision that denies a pharmaceutical company legal recourse when one of its patents is threatened by a generic drug company's announced plan to market a generic version of the drug covered by the patent. The decision was a setback for WLF, which filed a brief urging the Court to review the case. WLF argued that the decision below significantly undermines the financial incentives that the patent system normally provides to induce research and development of new, life-saving therapies. WLF also filed briefs in the case when it was in the appeals court.
|Supreme Court review denied|
More Information and Downloads:
10/24/2003: Download the Brief
Litigation Update: Court Declines to Review Decision Limiting Drug Firms' Patent Rights
Litigation Update: Court Declines To Reconsider Drug Patent-Rights Case
Litigation Update: Court Gives Mixed Signals In Drug Patent-Rights Case